Bliss GVS Pharma Limited (NSE:BLISSGVS)

Bliss GVS Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	2,133	231.4	249.55	219.15	126.35
Short-Term Investments	-	1,167	384.44	1,130	490.29
Trading Asset Securities	-	5.57	49.6	-	-
Cash & Short-Term Investments	2,133	1,404	683.59	1,349	616.64
Cash Growth	51.96%	105.34%	-49.34%	118.83%	55.25%
Accounts Receivable	4,384	4,043	3,852	3,928	4,638
Other Receivables	31.24	134.02	57.8	119.38	170.47
Receivables	4,415	4,178	3,910	4,048	4,810
Inventory	1,257	1,184	1,031	1,239	989.27
Prepaid Expenses	-	27.76	24.21	31.9	14.32
Other Current Assets	459.5	1,322	1,325	1,100	1,222
Total Current Assets	8,265	8,116	6,974	7,769	7,652
Property, Plant & Equipment	4,177	3,694	3,729	2,948	2,278
Long-Term Investments	43.85	80.2	568.59	36.75	620.13
Goodwill	77.11	77.11	77.11	77.11	77.11
Other Intangible Assets	2.3	1.07	2.29	3.83	5.79
Long-Term Deferred Tax Assets	-	-	33.33	-	-
Other Long-Term Assets	442.88	170.32	184.42	252.93	134.35
Total Assets	13,008	12,139	11,569	11,087	10,768
Accounts Payable	714.18	609.65	863.9	926.06	742.25
Accrued Expenses	-	59.43	55.09	47.86	50.93
Short-Term Debt	-	324.17	460.14	607.03	650.38
Current Portion of Long-Term Debt	511.29	197.98	113.63	210.32	211.11
Current Portion of Leases	44.1	27.55	11.14	9.42	13.18
Current Income Taxes Payable	37.74	18.66	26.56	66.49	86.01
Current Unearned Revenue	-	69.24	34.7	90.08	157.91
Other Current Liabilities	409.86	291.53	367.44	373.6	124.59
Total Current Liabilities	1,717	1,598	1,933	2,331	2,036
Long-Term Debt	198.46	355.92	406.9	232.22	326.04
Long-Term Leases	127.19	92.79	27.17	34.92	18.29
Long-Term Unearned Revenue	0.47	0.61	0.74	0.87	1.01
Long-Term Deferred Tax Liabilities	3	35.93	-	13.23	82.09
Total Liabilities	2,090	2,109	2,394	2,623	2,489
Common Stock	105.37	104.69	104.15	103.68	103.15
Additional Paid-In Capital	-	331.64	269.94	212.77	147.57
Retained Earnings	-	9,324	8,603	7,941	7,826
Comprehensive Income & Other	10,398	-88.46	-138.53	-70.73	5.38
Total Common Equity	10,504	9,672	8,839	8,187	8,083
Minority Interest	414.71	357.9	335.27	277.6	196.56
Shareholders' Equity	10,918	10,030	9,174	8,465	8,279
Total Liabilities & Equity	13,008	12,139	11,569	11,087	10,768
Total Debt	881.04	998.4	1,019	1,094	1,219
Net Cash (Debt)	1,252	405.27	-335.39	255.5	-602.36
Net Cash Growth	208.94%	-	-	-	-
Net Cash Per Share	11.81	3.82	-3.18	2.43	-5.71
Filing Date Shares Outstanding	105.71	104.69	104.15	103.68	103.36
Total Common Shares Outstanding	105.71	104.69	104.15	103.68	103.15
Working Capital	6,548	6,518	5,041	5,438	5,616
Book Value Per Share	99.37	92.39	84.87	78.97	78.36
Tangible Book Value	10,424	9,594	8,760	8,106	8,000
Tangible Book Value Per Share	98.61	91.64	84.10	78.19	77.56
Land	-	409.88	419.83	420.09	144.14
Buildings	-	1,369	1,437	1,059	1,055
Machinery	-	2,616	2,580	1,809	1,490
Construction In Progress	-	78.27	28.01	221.55	23.95

Source: S&P Global Market Intelligence. Standard template. Financial Sources.